Awad MM - Search Results

1

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer.

Alessi JV, Price A, Richards AL, Ricciuti B, Wang X, Elkrief A, Pecci F, Di Federico A, Gandhi MM, Lebow ES, Santos PMG, Thor M, Rimner A, Schoenfeld AJ, Chaft JE, Johnson BE, Gomez DR, Awad MM, Shaverdian N. Alessi JV, et al. Among authors: awad mm. J Immunother Cancer. 2023 Nov;11(11):e007618. doi: 10.1136/jitc-2023-007618. J Immunother Cancer. 2023. PMID: 37914383 Free PMC article.

2

Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.

Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Jänne PA, Hodi FS, Awad MM. Nishino M, et al. Among authors: awad mm. Cancer Immunol Res. 2016 Apr;4(4):289-93. doi: 10.1158/2326-6066.CIR-15-0267. Epub 2016 Feb 10. Cancer Immunol Res. 2016. PMID: 26865455 Free PMC article.

3

Nishino M, Ramaiya NH, Chambers ES, Adeni AE, Hatabu H, Jänne PA, Hodi FS, Awad MM. Nishino M, et al. Among authors: awad mm. J Immunother Cancer. 2016 Dec 20;4:84. doi: 10.1186/s40425-016-0193-2. eCollection 2016. J Immunother Cancer. 2016. PMID: 28018599 Free PMC article.

4

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, Bonomi PD, Ellison DM, Eaton KD, Fritsch H, Munzert G, Johnson BE, Socinski MA. Awad MM, et al. Lung Cancer. 2017 Feb;104:126-130. doi: 10.1016/j.lungcan.2016.12.019. Epub 2016 Dec 30. Lung Cancer. 2017. PMID: 28212994 Clinical Trial.

5

Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.

Leonardi GC, Oxnard GR, Haas A, Lang JP, Williams JS, Awad MM. Leonardi GC, et al. Among authors: awad mm. J Immunother. 2017 Jul/Aug;40(6):249-251. doi: 10.1097/CJI.0000000000000173. J Immunother. 2017. PMID: 28557813

6

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Dagogo-Jack I, Martinez P, Yeap BY, Ambrogio C, Ferris LA, Lydon C, Nguyen T, Jessop NA, Iafrate AJ, Johnson BE, Lennerz JK, Shaw AT, Awad MM. Dagogo-Jack I, et al. Among authors: awad mm. Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17. Clin Cancer Res. 2019. PMID: 30224342

7

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Immunother Cancer. 2019 Mar 28;7(1):87. doi: 10.1186/s40425-019-0572-6. J Immunother Cancer. 2019. PMID: 30922388 Free PMC article.

8

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M. Hida T, et al. Among authors: awad mm. J Thorac Imaging. 2020 Mar;35(2):101-107. doi: 10.1097/RTI.0000000000000413. J Thorac Imaging. 2020. PMID: 30985604

9

Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.

Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Ricciuti B, et al. Among authors: awad mm. J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17. J Clin Oncol. 2019. PMID: 31206316

10

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.

Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Aguilar EJ, et al. Among authors: awad mm. Ann Oncol. 2019 Oct 1;30(10):1653-1659. doi: 10.1093/annonc/mdz288. Ann Oncol. 2019. PMID: 31435660 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

329 results

Search Page